Matches 1 - 50 out of 332 1 2 3 4 5 6 7 >


Match Document Document Title
US20120021051 ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM  
A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for...
US20110046136 METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH  
The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of...
US20150174130 COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS  
Embodiments of the presently-disclosed subject matter include activators of HssRS that induce endogenous heme biosynthesis by perturbing central metabolism. These molecules are toxic to fermenting...
US20150164899 INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN  
This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed.
US20140080834 INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN  
This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed.
US20120039954 METHOD OF TREATING INSOMNIA  
A method of treating insomnia comprising administering to a subject a formulation including zaleplon, wherein the formulation is adapted to release the zaleplon after a lag time of at least about...
US20120121540 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections  
Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
US20130203777 Identification of Stabilizers of Multimeric Proteins  
Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are...
US20140037622 HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS  
Methods of treating a head and neck cancer are disclosed.
US20140213554 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR  
Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions...
US20110077250 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR  
The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with...
US20110224234 Polymorph B of N--N-methyl-acetamide  
The present invention relates to a method of treating anxiety, epilepsy, sleep disorders, and insomnia, for inducing sedation-hypnosis, anesthesia, and muscle relaxation, and for modulating the...
US20140107084 ULTRA LOW DOSE DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS  
The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep...
US20140194403 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS  
Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need...
US20110009353 TARGETING CDK4 AND CDK6 IN CANCER THERAPY  
The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell...
US20120088770 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO  
Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library...
US20140234254 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE  
The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially...
US20150157633 WNT PROTEIN SIGNALLING INHIBITORS  
The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment...
US20120122888 Potassium Channel Modulators  
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compositions comprising such compounds; and methods for...
US20120164209 ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING  
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
US20110076325 ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING  
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
US20110002985 ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING  
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
US20140288093 TREATMENT OF PROTEINOPATHIES  
The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore...
US20150018371 POSITIVE ALLOSTERIC MODULATORS FOR MELANOCORTIN RECEPTORS  
Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions...
US20110071115 PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS  
The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders...
US20080076773 Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes  
The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or...
US20140256677 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS  
Heterocyclylpyri(mi)dinylpyrazole of the formula (I) in which R1 to R5, X1, U, Q, W, Y, n, a, b have the meanings given in the description, and agrochemically active salts, to their use and to...
US20150216867 COMPOUNDS FOR USE IN GASTRIC COMPLICATION  
The present invention relates to the use of low molecular weight (lmw) compounds, especially lmw compounds with GPR4-affinity, in the treatment of diseases and disorders which includes...
US20150105377 Methods and Compositions for RAF Kinase Mediated Diseases  
The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable...
US20110142757 NOVEL COMPOUNDS AND THEIR USES IN DIAGNOSIS  
A compound of formula (I) wherein, X and Y independently bind TSPO, wherein X and Y are the same or different; and L is a linker that links X to Y; or a salt or solvate thereof. For preference, X...
US20120165336 Color Change Time Indicator for Packaging System  
Disclosed in certain embodiments is a pharmaceutical packaging system comprising: a receptacle comprising an openable seal for accessing the interior of the receptacle; a pharmaceutical dosage...
US20130005655 COMBINATION THERAPY USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP  
A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These...
US20140256720 CANCER TREATMENT USING BMP INHIBITOR  
Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In...
US20110288083 METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE  
The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first...
US20140066434 Methods and Compositions for Treating Parkinson's Disease  
The invention discloses methods and compositions for treating or preventing Parkinson's disease by administering a compound of Formula (I): or a pharmaceutically acceptable salt, solvate or...
US20130023412 Fungicidal Mixtures Based on Azolopyrimidinylamines  
Fungicidal mixtures based on azolopyrimidinylamines.
US20090105210 Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes  
The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment...
US20140005182 Aryl Methyl Benzoquinazolinone M1 Receptor Positive Allosteric Modulators  
The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the...
US20130078304 CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS  
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form...
US20120041002 SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS  
The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical...
US20130331401 Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates  
The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R1, X and Y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of...
US20150252049 MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS  
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric...
US20140154240 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT  
The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for...
US20140072554 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT  
The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for...
US20120003215 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT  
The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for...
US20120040999 P38 KINASE INHIBITING AGENTS  
Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: Formula (I); are inhibitors of p38 and are useful in the treatment of inflammation such as in the...
US20140343071 COMPOSITIONS AND METHODS FOR TREATING CANCER  
The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by...
US20090076034 DEUTERIUM-ENRICHED BMS-690514  
The present application describes deuterium-enriched BMS-690514, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20090062312 DEUTERIUM-ENRICHED INDIPLON  
The present application describes deuterium-enriched indiplon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20140329807 HETEROCYCLIC PROTEIN KINASE INHIBITORS  
The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein...

Matches 1 - 50 out of 332 1 2 3 4 5 6 7 >